|
|
|
SOUTH AFRICA: Indian first-line ARV registered
[This report does not necessarily reflect the views of the United Nations]
JOHANNESBURG, 26 April (PLUSNEWS) - Indian generic drug firm Cipla Medpro, this week announced one of its key antiretroviral (ARV) drugs had been registered in South Africa.
The drug Triomune - to be supplied through the local company, Enaleni Pharmaceuticals - was expected to help reduce the daily pill burden of HIV-positive patients from the current six or more tablets per day to only one pill in the morning and again at night.
"[This] is indeed a breakthrough and represents Cipla's commitment to making life-prolonging medicines accessible and affordable to the broader population," Trevor Edwards, CEO of Enaleni Pharmaceuticals said in a statement.
Triomune contains lamivudine, nevirapine and stavudine, which currently form part of first-line ARVs recommended by the South African Department of Health, and HIV Clinicians Society, as well as the World Health Organisation.
[ENDS]
:: MORE NEWS BRIEFS ::
|
|
|
|
|
|
|
|
|
|
| Links |
· AIDS Media Center
|
· The Global Fund to fight AIDS, Tuberculosis & Malaria
|
· International Community of Women Living with HIV/AIDS
|
· AEGIS
|
· International HIV/AIDS Alliance
|
PlusNews does not take responsibility for info in links supplied.
|
|
|
|
|
[Back] [Home Page]
Click here to send any feedback, comments or questions you have about PlusNews Website or if you prefer you can send an Email to Webmaster
Copyright © IRIN 2006
The material contained on www.PlusNews.org comes to you via IRIN, a UN humanitarian news and information service, but may not necessarily reflect the views of the United Nations or its agencies.
All PlusNews material may be reposted or reprinted free-of-charge; refer to the IRIN copyright page for conditions of use. IRIN is a project of the UN Office for the Coordination of Humanitarian Affairs.
|
